New drug duo aims to tackle Hard-to-Treat breast cancer

NCT ID NCT06100874

Ongoing Disease control Sponsor: Adrienne G. Waks Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests the safety and effectiveness of combining sacituzumab govitecan (Trodelvy) with trastuzumab (Herceptin) in 28 people with HER2+ metastatic breast cancer that has worsened after treatment with trastuzumab deruxtecan. The goal is to see how many participants' tumors shrink or disappear. The study is active but no longer recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sacituzumab govitecan (Trodelvy) and trastuzumab (Herceptin or Herceptin Hylecta)
What this could lead to: If it works, this could offer a new treatment option for people with HER2+ metastatic breast cancer who have already tried trastuzumab deruxtecan.
What could go wrong: This is a small, early-phase trial with only 28 participants, so results may not apply to everyone. The combination may cause side effects or not work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER FEMALE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm female breast carcinoma HER2 positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER FEMALE BREAST CANCER, METASTATIC HER 2 POSITIVE BREAST CANCER

Contacts and locations

Locations

DFCI @ South Shore Hospital

South Weymouth, Massachusetts, 02190, United States
Dana Farber Cancer Institite

Boston, Massachusetts, 02215, United States
Miami Cancer Institute at Baptist Health

Miami, Florida, 33176, United States
SCRI Oncology Partners

Nashville, Tennessee, 37203, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.